高级检索
殷科珊, 曹婕, 董婕, 江蓉蓉, 欧强, 张建良, 巫善明. 恩替卡韦与拉米夫定治疗乙型肝炎失代偿性肝硬化临床观察[J]. 实用临床医药杂志, 2011, (23): 80-82. DOI: 10.3969/j.issn.1672-2353.2011.23.030
引用本文: 殷科珊, 曹婕, 董婕, 江蓉蓉, 欧强, 张建良, 巫善明. 恩替卡韦与拉米夫定治疗乙型肝炎失代偿性肝硬化临床观察[J]. 实用临床医药杂志, 2011, (23): 80-82. DOI: 10.3969/j.issn.1672-2353.2011.23.030
shu
YIN Ke-shan, CAO Jie, DONG Jie, JIANG Rong-rong, OU Qiang, ZHANG Jian-liang, WU Shan-ming. Clinical study on treatment of Entecavir versus Lamivudine in patients with decompensated HBV-related cirrhrosis[J]. Journal of Clinical Medicine in Practice, 2011, (23): 80-82. DOI: 10.3969/j.issn.1672-2353.2011.23.030
Citation: YIN Ke-shan, CAO Jie, DONG Jie, JIANG Rong-rong, OU Qiang, ZHANG Jian-liang, WU Shan-ming. Clinical study on treatment of Entecavir versus Lamivudine in patients with decompensated HBV-related cirrhrosis[J]. Journal of Clinical Medicine in Practice, 2011, (23): 80-82. DOI: 10.3969/j.issn.1672-2353.2011.23.030
shu

恩替卡韦与拉米夫定治疗乙型肝炎失代偿性肝硬化临床观察

Clinical study on treatment of Entecavir versus Lamivudine in patients with decompensated HBV-related cirrhrosis

    摘要
  • 摘要: 目的 探讨恩替卡韦治疗乙型肝炎失代偿性肝硬化(DLC)患者的临床疗效和安全性.方法 63例Child-PughB级乙型肝炎DLC患者在综合治疗的基础上,分为恩替卡韦治疗组30例(给予恩替卡韦0.5mg口服,1次/d)和拉米夫定对照组33例(给予拉米夫定100 mg口服,1次/d),疗程均在48周以上.在治疗开始前、开始后1、12、24、48周分别检测血清乙肝病毒定量(HBV DNA)、乙型肝炎e抗原(HBeAg)、乙型肝炎e抗体(HBeAb)、肝肾功能、凝血功能、血清肌酐(SCr)、血常规和Child-Turcotte-Pugh分级(CPT评分)等指标.结果 恩替卡韦组有24例、拉米夫定组30例已完成48周治疗.恩替卡韦组治疗失代偿性乙型肝炎肝硬化与拉米夫定组疗效相似.拉米夫定组有7例出现耐药加用阿德福韦酯联合治疗,恩替卡韦组无1例发生耐药.恩替卡韦组2例、拉米夫定组3例发生原发性肝癌.结论 恩替卡韦治疗乙型肝炎DLC1年临床疗效较明显,无耐药发生,是乙型肝炎DLC抗病毒治疗的有效药物.

     

    • HTML全文
    • 参考文献(9)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回